Table 1.
Clinical trials related to the therapeutic use of CD28 manipulation, such as CAR-T cell therapy and monoclonal antibodies.
| Malignancy | Phase | N | Trial Name | Clinical Trial Identifier | Therapeutics | References |
|---|---|---|---|---|---|---|
| Relapsed or Refractory Acute Lymphoblastic Leukemia | 1 | 5 | Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients with Acute Lymphoblastic Leukemia | NCT02186860 | Third Gen CAR-T cells containing CD28+CD137 | [71] |
| Glioblastoma | 1 | 17 | CMV-Specific Cytotoxic T Lymphocytes Expressing CAR Targeting HER2 in Patients with GBM (HERT-GBM) | NCT01109095 | Second Gen CMV-selected CAR-T cells against HER2 containing CD28.zeta signaling domain | [72] |
| Rheumatoid Arthritis | 1/2 | 18 | Safety, Tolerability, Pharmacodynamics and Efficacy Study of TAB08 in Patients with Rheumatoid Arthritis | NCT01990157 | TAB08 | |
| Solid Neoplasms | 1 | 38 | Dose Escalation Study of TAB08 in Patients with Advanced Solid Neoplasms (TAB08) | NCT03006029 | TAB08 | [73] |
| Systemic Lupus Erythematosus | 2 | 730 | Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus | NCT02265744 | Lulizumab pegol (monoclonal antibody against CD28) |